| Ytd | -17.60% | |
| 1y | 11.33% |
| Open | 29.57 | Prev Close | 29.36 | Low | 28.40 | High | 29.68 | Mkt Cap | 3.38B |
| Vol | 2.67M | Avg Vol | 2.26M | EPS | -4.67 | P/E | N/A | Forward P/E | -6.71 |
| Beta | 0.68 | Short Ratio | 12.59 | Inst. Own | 66.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-28 | 50-d Avg | 33.95 | 200-d Avg | 33.30 | 1yr Est | 92.39 |
VKTX News
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation
VK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phas
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Viking Therapeutics Inc. (NASDAQ:VKTX) shares are dropping Tuesday amid a broader risk-off session,
Viking Therapeutics shares are dropping Tuesday amid a risk-off trade, though its longer-term uptren
Viking Therapeutics NASDAQ: VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 de
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the
Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue fro
Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly an
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% mov
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classif
Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-for
Jupiter Topco LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) in the undefined
AXQ Capital LP grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) by 164.0% during
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% mo
Viking Therapeutics' shares could soar as it makes progress with its leading candidates. However, th
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clin
US stock futures lower, MongoDB shares down 13.4% in pre-market trading after earnings beat estimate
Canada Pension Plan Investment Board bought a new position in shares of Viking Therapeutics, Inc. (N
This whale alert can help traders discover the next big trading opportunities. Whales are entities w